I have spoken about multiple strategies being undertaken, including strengthening our capability, working with global regulators, working with manufacturers, strengthening domestic biomanufacturing as that strengthens work to resolve issues domestically, and looking at the experience from the pandemic in the critical drug reserves. We're looking at multiple strategies.
Obviously, our goal is to ensure that Canadians have access to the medications they need when they need them, and that they are safe, of high quality and effective. We will continue to work toward that, supporting, in particular in this moment, children and infants and their parents and caregivers to address this current challenge with pediatric analgesics as quickly as possible and using every tool possible.